Trabectedin is particularly effective in myxoid liposarcomas, displacing the fusion protein FUS-CHOP from its target DNA promoters and impairing the trans-activating capacity of the FUS-CHOP chimaeras, leading to a reversal effect of the oncogenic program and phenotype in myxoid liposarcoma cells, restoring their ability to drive adipocyte differentiation [104,105]. Here, FUS is linked to myxoid liposarcoma.